Hello! Welcome to ONTORES!

CN +86-21-68388652

Your shopping cart is empty.

According to the order.

Ordering Center

Peptide modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma

Published: 2016-11-16

Keyword:

Article from our customer: Kairong Shi, Journal of Controlled Release,2015.

 

Background: The use of pH-responsive cell-penetrating peptides (CPPs) is an attractive strategy for drug delivery in vivo, however, they still could not actively target to the desired sites. Here, we designed a pH-responsive CPP (TR) with the ability of active targeting to integrin αvβ3.

 

Results: TR-Lip could not only actively target to αvβ3-overexpressing cells compared to TH-Lip, but also significantly increased cellular uptake compared to RGD-Lip. At the concentration of 20 μg/mL paclitaxel (PTX), the killing activity of PTX-loaded TR-Lip (PTX-TR-Lip) against B16F10 cells was 1.80-, 1.45-, 1.30-, 1.15-time higher than that of PTX-loaded PEG-, RGD-, TH-modified liposomes and free PTX at pH 6.5, respectively. In vivo imaging displayed the maximum accumulation of DiD-labeled TR-Lip at tumor sites compared to the other groups. Tumor inhibition rate of B16F10 tumor-bearing mice treated with PTX-TR-Lip was 85.04%, relative to that of PBS. In B16F10 tumor-bearing mice, PTX-TR-Lip showed significantly higher survival rate compared with the other groups.

 

Conclusion: All the results in vitro and in vivo suggested that TR-Lip would be a potential delivery system for PTX to treat integrin αvβ3-overexpressing tumor-bearing mice.

Fig. 1. Schematic design of TR-Lip for integrin αvβ3-overexpressing tumor-targeted drug delivery. Tumor pH-induced TR-Lip for selective targeting to integrin αvβ3-overexpressing cells, improved cellular uptake, and enhanced tumor penetration.

 

In this article, TH peptide with a terminal cysteine (AGYLLGHINLHHLAHL(Aib)HHILCys), TR peptide with a terminal cysteine [c(RGDfK)-AGYLLGHINLHH LAHL(Aib)HHIL-Cys,lysine connected with alanine by covalent bonds]

were synthesized according to the standard solid phase peptide synthesis by ZheJiang Ontores Biotechnologies Co. Ltd. (Hangzhou, China).


As a leading Biotech company over world, Ontores committed to provide professionally high quality and comprehensive proteomic and genomic industry solution to our global customers. Ontores offers innovative solutions for antibodies, building blocks, oligonucleotides and peptides and carries a broad spectrum of bio-reagents that will meet everyone’s need in their multi-disciplinary research. Ontores also provides cutting edge custom services including antibody production, contract research services and peptide synthesis.